Kornimate/medical-research-clean huggingface dataset:
late stent strut apposition and coverage after drug-eluting stent implantation by oct in patients with ami

Conditions: Coronary Artery Disease; Coronary Disease; Myocardial Ischemia; Arterial Occlusive Diseases; Arteriosclerosis; Cardiovascular Diseases; Heart Diseases; Vascular Diseases

Summary: the purpose of this study is to evaluate the incidence of late incomplete stent apposition (isa) and un-coverage by optical coherence tomography (oct) following everolimus-eluting stent (ees) with bioabsorbable polymer (synergy™, boston scientific,nattick, ma, usa) versus zotarolimus-eluting stent (zes) with permanent polymer(resolute onyx™, medtronic, santa rosa, ca, usa) implantation in patients with ami at 12 months.

it has been known that persistence of polymer may affect the late/very late safety and efficacy of drug eluting stent (des) although polymer provides a reservoir for programmed drug release. newer durable polymers may have enhanced biocompatibility and seem to be associated with improved clinical outcomes. however, they have still been incriminated in the occurrence of inflammation, neo-atherosclerosis, and thrombosis. therefore, the investigators will evaluate the vascular tissue reaction after different kinds of des implantation under the high thrombogenic circumstance of acute myocardial infarction (ami).

Eligibility criteria:
inclusion criteria: * acute myocardial infarction including st-segment elevation myocardial infarction (stemi) or non st-segment elevation myocardial infarction (nstemi) treated with pci * patient ≥ 18 years of age * patient judged suitable to receive anti-platelet drugs of asa and ticagrelor for at least 12 months after the procedure * the patient or guardian agrees to the study protocol and the schedule of clinical and angiographic, oct follow up and provides informed consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site. * culprit lesion exclusion criteria: * the patient has a known hypersensitivity or contraindication to any of the following medications: heparin, abciximab, aspirin, ticagrelor, everolimus, zotarolimus, polymer, platinum chromium, cobalt chromium, contrast media * female of childbearing potential unless a pregnancy test is negative or who possibly plan to become pregnant any time after enrollment * cardiogenic shock * patient with left ventricular ejection fraction \<30% * patient with left main disease * patient with in-stent restenosis (isr) at target vessel (either bare metal stent or des, non-target vessel isr is permitted) * patient with impaired renal function (creatinine \>2.0mg/dl) * patient with inadequate oct images quality due to severe calcification, vessel tortuosity and artifacts * bifucation lesion needs complex procedure with insert two or more drug eluting stents. * lesion length \>30mm

Keywords: optical coherence tomography everolimus-eluting stent zotarolimus-eluting stent
plasma adiponectin level and sleep structures in children with prader-willi syndrome

Conditions: Prader-Willi Syndrome; Obesity

Summary: context: adiponectin is an adipose tissue-derived hormone with an insulin sensitizing effect, and has been related to obstructive sleep apnea syndrome. in addition, children with prader-willi syndrome (pws) suffer from excessive daytime sleepiness and the abnormality of rapid eye movement (rem) sleep. objective: to determine if the sleep stages are related to the plasma levels of adiponectin, resistin, and rbp4 (retinol binding protein-4), and whether these relationships are influenced by age, obesity and insulin resistance.

this comparative study was carried out in 28 pws children and 18 controls. the enrolled pws children were volunteers out of a pool of approximately 100 pws children followed at samsung medical center \[median age 8.0 years, interquartile range (7.0-10.5 years), bmi: median 24.2 kg/m2 (23.0-27.5 kg/m2)\] and 18 obese healthy children \[median age 9.0 years interquartile range (7.0-11.0 years), bmi: median 24.2 kg/m2 interquartile range (23.1-27.6 kg/m2)\].

Eligibility criteria:
inclusion criteria: * prader willi syndrome healthy children exclusion criteria: * history of seizure, * mental or brain illness, * adenoidectomy, * tonsillectomy, * craniofacial anomalies and any treatment at the time of the study.

Keywords: rem sleep adiponectin prader-willi syndrome
neuroaxial labour analgesia

Conditions: Labor Analgesia

Summary: the primary outcome of this clinical trial is to compare the pain scores during labour and delivery of combined spinal epidural without intrathecal opioids and dural puncture epidural the secondary objective of this study is to compare the and fetomaternal outcomes


Eligibility criteria:
inclusion criteria: 1. nulliparous parturient 2. singleton, vertex gestation at term (37-42 weeks) 3. less than 5 cm dilation 4. request an epidural technique for labor analgesia exclusion criteria: 1. hypersensitivity to local the study drugs 2. clinically significant disease , including diseases of pregnancy (i.e preeclampsia, gestational diabetes) 3. any contraindication to the administration of an epidural technique 4. risk factor for cesarean delivery. 5. fetal anomalies
a trial of neoadjuvant everolimus plus letrozole versus fec in women with er-positive, her2-negative breast cancer

Conditions: Breast Cancer

Summary: this open, randomized pilot feasibility trial is to evaluate the feasibility and effect of neoadjuvant everolimus plus letrozole versus neoadjuvant fluorouracil, epirubicin plus cyclophosphamide (fec) in treating postmenopausal women with er-positive, her2-negative breast cancer. forty postmenopausal stage m0, er-positive, her2-negative invasive breast cancer women who had a primary tumor \> 2cm by imaging or an axillary lymph node \> 2cm by imaging were randomly (1:1) enrolled to receive neoadjuvant everolimus plus letrozole for 18 weeks or neoadjuvant fec for 6 cycles before surgery. the primary objective is to determine the feasibility of neoadjuvant everolimus plus letrozole in postmenopausal patients with er-positive, her2-negative breast cancer. secondary aims are to compare the ultrasound response rate, pathological complete response (pcr) rate, breast-conserving surgery rate, toxicities, and changes in the percentages or counts of peripheral blood cd4+ t cells, cd8+ t cells, tumor-specific ctls, t helper cells (th), regulatory t cells (treg), and nk cells and changes in tumor ki67 index (pre- versus post- neoadjuvant therapy).


Eligibility criteria:
inclusion criteria: * the patients signed the written informed consent * the patients present with non-metastatic unilateral invasive er-positive, her2-negative breast cancer with a primary breast tumor \> 2cm by imaging or an axillary lymph node \> 2cm by imaging. * postmenopausal women with age less than 70 years old. * the patients have no history of hormone therapy, chemotherapy, breast cancer surgery and radiotherapy. * the patients have normal cardiac functions by echocardiography. * the patients' ecog scores are ≤2. * the patients can swallow pills. * the results of patients' blood tests are as follows: * hb≥90g/l; * wbc≥4e+9/l; * plt≥100e+9/l; * neutrophils≥1.5e+9/l; * alt and ast ≤ triple of normal upper limit; * tbil ≤ 1.5 times of normal upper limit; * creatinine ≤ 1.5 times of normal upper limit. exclusion criteria: * the patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus; * the patients have active infections that were not suitable for chemotherapy; * the patients have severe non-cancerous diseases. * the patients have bilateral breast cancers or multifocal breast cancers or inflammatory breast cancers. * the patients have a history of previous treatment with mtor inhibitors. * the patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials. * the patients are in some special conditions that they cannot understand the written informed consent, such as they are demented or hawkish. * the patients have allergic history or contraindication of any of the interventional drugs.
acute heart failure monitoring via inferior vena cava ultrasound

Conditions: Chronic Heart Failure

Summary: known before diagnosed heart failure and used diuretic therapy patients will be admitted in this study.the objective of this work is whether the inferior vena cava ultrasound can be used for management of acute heart failure therapy. and investigators will calculation correlation of extracted urine amount with inferior vena cava diameter change. researchers will not interfere to standard recommended treatment protocol, researchers will correlated the urine amount and changed vital signs with therapy with vena cava inferior diameter.


Eligibility criteria:
inclusion criteria: * adult patients (\> 18 years of age) of both sexes) * non-trauma patients * non- pregnant patients * all patients will be accepted for this study, that known heart failure and must be taken diuretic therapy because of volume overload exclusion criteria: * cardiac tamponade * aortic dissection * patients who had suffered cardiopulmonary arrest or been intubated

Keywords: inferior vena cava ultrasound acute heart failure management decompensation
ecg-guided immediate primary pci for culprit vessel to reduce door to device time

Conditions: Myocardial Infarction

Summary: no consensus exists about which coronary artery should be firstly catheterized in primary percutaneous coronary intervention (pci). the aim of the present study was to compare door-to-balloon time (d2b) of ecg guided immediate infarct-related artery (ira) pci with traditional complete coronary angiography followed by pci for the treatment of st segment elevation myocardial infarction (stemi) patients. primary endpoint is door to device (d2d) time. secondary end-points are: puncture to device (p2d) time,first medical contact to device (fmc2d) time,incidence of radial artery spasm and occlusion, contrast amount, fluoroscopy time, cumulative air kerma(cak) and dose area product(dap).


Eligibility criteria:
inclusion criteria: * patient must be \> 18 years of age * patients have typical chest pain for at least 20 minutes and have ecg changes typical for stemi (st elevation≥2mm in two continuous precordial leads or st elevations≥1mm in two limb leads or new left bundle branch block) or ecg changes compatible with true posterior mi * symptoms ≥ 30 min and ≤12 hours * patient and treating interventional cardiologist agree for randomization * patient provides written informed consent * diagnostic and therapeutic intervention performed through transradial artery approach * palpable radial artery. exclusion criteria: * concurrent participation in other investigational study * current platelet count \<100 x 10\^9cells/l or hgb \<10 g/dl * absence of radial artery pulsation * active bleeding or significant increased risk of bleeding, severe hepatic insufficiency, current peptic ulceration, proliferative diabetic retinopathy * uncontrolled hypertension * prior cabg surgery * fibrinolytic therapy for current mi treatment * patient have a life expectancy of \<180days
sensory-motor integration for speech rehabilitation in patients with post-stroke aphasia

Conditions: Aphasia Non Fluent; Stroke

Summary: semo is a multidisciplinary project (language sciences, cognitive psychology and neuropsychology, physical medicine and rehabilitation, neurology, speech-language pathology, functional neuroimaging and engineering sciences) that aims first, to test and develop a novel speech rehabilitation program designed for patients with non-fluent aphasia and, second, to better describe neural reorganization after successful recovery. to this end, the investigators will conduct a prospective monocentric cross-over study, including two cohorts of post-stroke aphasic patients and two control groups.

in this project, the investigators propose to evaluate the effectiveness of a new rehabilitation program, based on illustration of speech articulators, to improve speech in patients with non-fluent aphasia. the instigators' method is based on the reinforcement of the interaction between perceptual and motor representations, thanks to the innovative ultraspeech device. the investigators will exploit a fundamental psycholinguistic principle, which postulates that speech is based both on the activation of the system controlling the motricity of effectors related to word articulation (action) and on the auditory or visual representation of words (perception). the sensory-motor interaction method that the investigators propose allows the patient to perceive phonemes and visualize on a computer screen the movements of the tongue and lips previously recorded by a healthy speaker, typically a speech therapist. through repeated exercises, the patient is trained to produce sounds correctly, using the correct pronunciation and articulatory movements of the reference speaker as a model. the investigators will compare patients who will follow a classical speech and language therapy rehabilitation program followed by an 'enriched' rehabilitation program including rehabilitation based on sensory-motor interaction associated with speech and language therapy, and vice versa. in order to judge the favorable effect of the rehabilitation program including sensory-motor integration, the following measures will be considered: (a) language skills, (b) phonemic quality, (c) inner speech abilities and (d) cognitive function. brain language networks will be evaluated with neuroimaging.

Eligibility criteria:
inclusion criteria: * patients with non-fluent aphasia after lesion in the dominant hemisphere for language * native speakers of french * normal or corrected to normal vision * satisfying all criteria for the mri examination exclusion criteria: * patients with comprehension deficits, hemi-spatial neglect or upper limb apraxia

Keywords: post-stroke aphasia non-fluent aphasia speech rehabilitation neuroimaging neural reorganization recovery
use of a tga and tem in the assessment of the efficacy of treatment with apcc or rfviia

Conditions: Haemophilia

Summary: occurrence of inhibitors to coagulation factor viii is diagnosed in \~30% patients with haemophilia a. presence of inhibitor with a titre \>5 bu/ml requires the use of by-passing agents: recombinant activated factor viia concentrate (rfviia) and/or activated prothrombin complex concentrate (apcc). similarly, haemorrhagic complications in patients with acquired haemophilia and inhibitor titre \>5 bu/ml should be treated with by-passing agents. response to treatment with by-passing agents is patient-specific, and can vary in the same patient during subsequent bleedings. some patients have good response to both products, however in other patients a better bleeding control is provided by one of the mentioned above agents (apcc or rfviia). there are clinical situations when severe bleedings requires an alternate use of both these agents. traditional methods of laboratory tests used post-treatment in patients with haemophilia without inhibitors are useless in the presence of inhibitor. laboratory monitoring of therapy with by-passing agents is possible with the use of global tests for the coagulation process assessment, which are as follows: thrombin generation assay (tga) and thromboelastometry (tem). several studies revealed that tga allows a monitoring of therapy with by-passing agents in patients with haemophilia a and inhibitor - the choice of the most effective treatment option - agent type and its dose, as well as laboratory assessment of treatment efficacy. up to date, laboratory tests assessing the efficacy of by-passing agents in patients with acquired haemophilia were not conducted. in factor viii or ix deficiency conditions, fibrin's fibres generated by thrombin are morphologically thicker, and blood clots have increased susceptibility to fibrinolytic enzymes. blood clot stability may be assessed with the use of thromboelastometry (tem). we can hypothesize that simultaneous use of tga and tem methods may allow for an assessment of patient's individual response to therapy with by-passing agents. clinical significance of the minimal dose of apcc and rfviia, needed to tga and tem normalization, requires further studies. tests' purpose: examination of the hypothesis that simultaneous use of thrombin generation assay (tga) and thromboelastometry (tem) may facilitate the choice of optimal therapy with by-passing agents and laboratory monitoring of efficacy of those agents in patients with acquired haemophilia or haemophilia a with inhibitor.

this section is not applicable

Eligibility criteria:
inclusion criteria: * patients with acquired haemophilia * patients with congenital haemophilia a with inhibitor exclusion criteria:

Keywords: haemophilia tga tem
chemoprevention with folic acid

Conditions: Colon Cancer; Adenoma; Colonic Polyps

Summary: colorectal neoplasia is the second most common cancer in the united states and other western countries with about 140,000 newly diagnosed cases per year in the united states with a mortality rate of about 40%. the identification of a specific natural or synthetic compound with the ability to reverse or suppress the process of colon carcinogenesis would have profound implication in the development of colorectal adenomas and their subsequent transformation to colon cancer. furthermore, the establishment of a correlative relationship between biomarkers of cell proliferation, differentiation, apoptosis and adenoma recurrence would provide pivotal data required to elucidate cell signaling mechanisms in future colon cancer chemoprevention trials.


Eligibility criteria:
asymptomatic individuals from the age of 18 -80 years, undergoing clinically indicated colonoscopy for colon polyps noted on screening flexible sigmoidoscopy or as routine surveillance for a history of colon polyps, who are found to have at least one adenoma \> 0.5cm will be eligible for entry.
implementing fit kit colorectal cancer (crc) screening in high risk populations

Conditions: Colorectal Cancer

Summary: the purpose of this study is to understand best strategies for engaging high risk populations in a primary care setting to improved adherence to colorectal cancer screening guidelines. the results will be used to identify best practices that are scalable to other high-risk populations who are due or overdue for colorectal cancer (crc) screening.

this is a prospective implementation science study that will test 4 different approaches to increase colorectal cancer screening in a local primary care setting that provides services to individuals who are under-resourced. the interventions will include reminders from primary care providers with and without additional information and/or services to help complete colorectal cancer screening. a review of electronic medical records will be used to identify baseline information assessing risk factors and personal and family crc history. for arm 3 of the study, participants may elect to enroll in our existing health navigation program. if so, additional baseline information will be collected, including information on social determinants of health (sdoh). for arm 4 of the study, a questionnaire will be used to assess knowledge about colorectal cancer screening. the questionnaire will be repeated after the intervention (informational video). for all arms of the study, the primary outcome (engagement on crc screening, receipt of crc screening, results of crc screening) will be collected through epic.

Eligibility criteria:
inclusion criteria: * be 50-74 years of old at the time of enrollment * have one valid medical encounter with cshhc columbus ave. location or dixwell location between the dates of 11/01/2019 and 11/30/2020 exclusion criteria: • documented history of colorectal cancer

Keywords: health screening
comparing the establishment of operation space between high position and low position in endoscopic thyroid surgery

Conditions: Thyroid Cancer; Endoscopy

Summary: patients in our department endoscopic thyroidectomy were randomly divided into high position and low position established operating space group established operating space group. the thyroid size, patient bmi, operation time, and intraoperative blood loss were compared between the two groups.

patients in our department endoscopic thyroidectomy were randomly divided into high position and low position established operating space group established operating space group.the sternum angle level is used as the dividing line between the two groups。the thyroid size, patient bmi, operation time, and intraoperative blood loss were compared between the two groups.

Eligibility criteria:
inclusion criteria: * patients with endoscopic thyroid surgery * no previous neck surgery exclusion criteria: * patients undergoing lateral neck lymph node dissection during the same period
multi-site trial of navigation vs treatment as usual to improve initiation of timely adjuvant therapy

Conditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Oropharynx Cancer; Oral Cavity Cancer; Larynx Cancer

Summary: the goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (endure) with treatment as usual (tau) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. the main questions the trial aims to answer are: 1. does endure improve initiation of timely port relative to treatment as usual? 2. what are the mechanisms through which endure improves timeliness to treatment? 3. what are the barriers and facilitators to the implementation of endure into routine clinical care?

in this hybrid type 1 effectiveness-implementation study, the investigators will conduct a stepped-wedge cluster randomized trial with cancer centers (n=4; 484 patients) randomized to sequentially deliver treatment as usual (tau) then endure to patients with head and neck cancer undergoing surgery and postoperative radiation therapy (port). the trial will assess the effect of endure vs tau on improving initiation of timely port (primary objective) and the underlying mechanisms of endure (secondary objective). the investigators will concurrently conduct a mixed-methods study with quantitative measures of implementation outcomes and qualitative data about implementation determinants from semi-structured interviews with key stakeholders and site visits (exploratory objective).

Eligibility criteria:
inclusion criteria: 1. age \>/= 18 years 2. squamous cell carcinoma (scc) (or histologic variant) of the oral cavity, oropharynx, hypopharynx, larynx, unknown primary, paranasal sinuses, or nasal cavity 3. american joint committee on cancer (ajcc) 8th edition clinical t3-4 or \>/= n1 scc of the oral cavity, oropharynx, hypopharynx, larynx, paranasal sinuses, nasal cavity, or unknown primary 4. no history of radiation therapy for treatment of hnscc in the definitive or adjuvant settings that would, at the discretion of the enrolling clinician, affect the patient's need for adjuvant rt 5. plan for curative intent surgery at one of the participating centers 6. plan for port (regardless of whether it is at the surgical center) with or without concurrent chemotherapy following curative intent surgery based on the expectation of at least one of the following adverse features on final pathologic evaluation: pt3 or pt4 primary, n1 or greater nodal disease, perineural invasion (pni), or lymphovascular invasion (lvi). exclusion criteria: 1. inability to speak or read english or spanish. 2. severe mental illness that would prevent trial participation. 3. hpv-positive opc or unknown primary scc staged as ct1-2n1 with a single ipsilateral ln \< 3 cm 4. synchronous untreated malignancy expected to impact life expectancy